At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
LY3526318 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3526318 and Placebo for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn more about how the drug is absorbed in to the blood stream and how it is eliminated from the body. The safety and tolerability of LY3526318 will also be evaluated when given by mouth either by single or multiple doses to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 44 days and Part B will last up to 50 days, including screening and follow-up.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionApr 2021
TodayJul 2026
First PostedDec 23, 2020
Enrollment StartDec 29, 2020
Primary CompletionApr 21, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.5 years ago
Interventions
LY3526318drug
Administered orally.
Placebodrug
Administered orally.